Severe Hemolytic Anemia and Metabolic Acidosis at Birth with Glutathione Synthetase Deficiency and Progressive Neurological Symptoms on Follow-Up.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
13 Apr 2023
13 Apr 2023
Historique:
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
BACKGROUND Glutathione synthetase deficiency (GSD) is a rare autosomal recessive disorder caused by glutathione synthetase (GSS) gene variants that occur in 1 in 1 million individuals. The severe form of GSD is characterized by hemolytic anemia, metabolic acidosis with 5-oxoprolinuria, progressive neurological symptoms, and recurrent bacterial infections. This case report presents a male Japanese infant with severe hemolytic anemia and metabolic acidosis at birth caused by GSD, who developed progressive neurological symptoms on follow-up. CASE REPORT A Japanese male term infant developed severe hemolytic anemia and metabolic acidosis in the early neonatal period. We suspected GSD based on his symptoms and a high 5-oxoproline urine concentration. We began correcting his metabolic acidosis and administering vitamins C and E supplements. The patient required blood transfusion twice during the acute phase for hemolytic anemia. After age 1 month, he maintained good control of metabolic acidosis and hemolytic anemia. A definitive diagnosis of GSD was made based on high concentrations of 5-oxoproline in urine, low concentrations of glutathione and GSS activity in erythrocytes, and genetic testing. Several episodes of febrile convulsions were started at age 11 months, but none occurred after 2 years. At the last follow-up at age 25 months, metabolic acidosis and hemolytic anemia were well controlled, but he had mild neurodevelopmental delay. CONCLUSIONS This case report shows that GSD can present with severe hemolytic anemia and metabolic acidosis at birth, and manifest with subsequent neurological impairment despite early diagnosis and treatment. Therefore, a careful long-term follow-up that includes neurological evaluation is essential for patients with GSD.
Identifiants
pubmed: 37050856
pii: 938396
doi: 10.12659/AJCR.938396
pmc: PMC10106969
doi:
Substances chimiques
Glutathione Synthase
EC 6.3.2.3
Pyrrolidonecarboxylic Acid
SZB83O1W42
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e938396Références
Genomics. 1995 Dec 10;30(3):617-9
pubmed: 8825653
Fetal Pediatr Pathol. 2015 Feb;34(1):18-20
pubmed: 25166299
Rinsho Ketsueki. 2021;62(5):472-479
pubmed: 34248124
Brain Dev. 2016 May;38(5):481-90
pubmed: 26612486
Fetal Pediatr Pathol. 2020 Feb;39(1):38-44
pubmed: 31198081
Braz J Med Biol Res. 2018 Jan 11;51(3):e6853
pubmed: 29340523
Blood. 1994 Dec 1;84(11):3613-36
pubmed: 7949118
Rinsho Ketsueki. 1996 Apr;37(4):329-34
pubmed: 8847804
Hum Genome Var. 2022 Jan 12;9(1):1
pubmed: 35022413
J Pain Palliat Care Pharmacother. 2008;22(1):45-46
pubmed: 28792816
J Neurochem. 1999 Sep;73(3):889-902
pubmed: 10461878
Hum Genet. 2005 Apr;116(5):384-9
pubmed: 15717202
Cell Mol Life Sci. 2005 Sep;62(17):1938-45
pubmed: 15990954
Orphanet J Rare Dis. 2007 Mar 30;2:16
pubmed: 17397529
J Hum Genet. 2016 Jul;61(7):669-72
pubmed: 26984560
Am J Clin Nutr. 1971 Jan;24(1):7-13
pubmed: 4923466
J Pediatr. 2001 Jul;139(1):79-84
pubmed: 11445798